# Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

> **NCT06178445** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 24 (estimated)

## Conditions studied

- Biliary Tract Cancer
- HER2 Gene Mutation
- HER2

## Interventions

- **DRUG:** SOC plus trastuzumab and pembrolizumab

## Key facts

- **NCT ID:** NCT06178445
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-17
- **Primary completion:** 2026-12
- **Final completion:** 2027-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06178445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06178445, "Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06178445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*